FRAMINGHAM, MA -- (MARKET WIRE) -- October 23, 2006 -- Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is pleased to announce that our ongoing IoGen™ pivotal Phase III clinical study for breast pain and tenderness associated with fibrocystic breast disease is receiving increased internet exposure. Symbollon’s trial for IoGen™ can currently be found on approximately eight hundred web pages through Google’s search engine, with presence on WebMD, Centerwatch, Topix.net, Biospace.com, Sheryl Crow.com and NewsRx.com. There are also several chat boards and blogs that are mentioning the trial which is creating an infectious distribution of information about IoGen™, Symbollon, and our pivitol Phase III study. This web presence, along with other advertising efforts, like our participation at breast health events and women’s expos, is part of Symbollon’s overall effort to complete the patient enrollment for the IoGen Phase III study.
